Home › Funds › venBio Partners LLC › LYEL

venBio Partners LLC position in LYEL

LYELL IMMUNOPHARMA INC · Health Care

venBio Partners LLC reported holding 337,697 shares of LYEL (LYELL IMMUNOPHARMA INC) in its Q2 2026 13F filing — a position valued at US$4.7M, representing 0.91% of its reported portfolio and ranking #7 among its reported holdings. venBio Partners LLC has disclosed LYEL holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)337.70K sh
Reported value held$4.74M
Portfolio Weight0.91%
First reportedQ4 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How venBio Partners LLC's LYEL position evolved

venBio Partners LLC first disclosed a stake in LYEL in Q4 2024 at 7,102,190 shares (US$4.5M). The position peaked in Q4 2025 at 337,697 shares, worth US$10.4M. Across 7 filings, venBio Partners LLC increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 337,697 shares valued at US$4.7M. Notable position changes include a 93% trim in Q2 2025 (shares rose 84% over the following quarter), a 29% trim in Q4 2025 (shares fell 35% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 7.10M $4.55M New
Q1 2025 7.10M $3.82M Hold
Q2 2025 473.48K $4.19M Reduce
Q3 2025 473.48K $7.69M Hold
Q4 2025 337.70K $10.39M Reduce
Q1 2026 337.70K $6.77M Hold
Q2 2026 337.70K $4.74M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LYEL and 13F data

LYEL (LYELL IMMUNOPHARMA INC) is a Health Care company. 31 other funds we track also report a position in LYEL — the largest reported positions include ARCH Venture Management, LLC (US$45.5M), GSK plc (US$21.3M), Orland Properties Ltd (US$10.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LYEL

All LYEL fund holders →

FAQ

How long has venBio Partners LLC held LYEL?

venBio Partners LLC has disclosed LYEL holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

What is venBio Partners LLC's current position in LYEL?

As of Q2 2026, venBio Partners LLC holds 337.70K shares of LYEL (LYELL IMMUNOPHARMA INC), valued at $4.74M, representing 0.91% of its reported portfolio and ranking #7.

Has venBio Partners LLC been buying or selling LYEL?

In the latest 13F filing (Q2 2026), venBio Partners LLC held unchanged its position in LYEL. The position peaked in Q4 2025 at 337.70K shares.

Which other funds hold LYEL?

Other major institutional holders of LYEL include ARCH Venture Management, LLC, GSK plc, Orland Properties Ltd, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.